German diagnostics set to lose pillar of strength
This article was originally published in Clinica
The roof over the in vitro diagnostics industry in Germany will stay up, albeit without one of its main pillars: Dierk Meyer-Luerssen will leave the national diagnostics industry association, the VDGH, of which he has been key component for 31 years, in 2009. The industry will be hoping that Mr Meyer-Luerssen's successor will be able to match his technical insight, knowledge and general ability to "convey the message" for an industry that has grown from E100m in 1977 to almost E2bn ($3.12bn) today - E2.2bn including non-VDGH adherents. That message has always been of vital nature of early diagnosis and optimum use of IVDs and of the importance of reimbursement for new tests. The VDGH director, who will be succeeded by association director Dr Martin Walger, has consistently been an energetic proponent of fair treatment for an industry that has to struggle - however inconceivable that may be - for attention and funding, in Germany as elsewhere. Clinica, among others, will miss his clarity and ability to convey messages about complex technologies in a clear - and often forthright -manner. See this issue, page 23.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.